Sarah Dohan is an associate at Ropes & Gray, practicing in the health care group. Sarah advises hospitals, health systems, pharmaceutical companies, health care investors, academic medical centers, and other health care organizations on a broad range of transactional, regulatory enforcement, and compliance matters.

During law school, Sarah served as an articles editor for the Stanford Law Review and a managing editor for the Stanford Law & Policy Review. She was also president of Stanford Law Women in Politics, co-president of the BioLaw and Health Policy Society, and a research assistant for Professor Roland Vogl. Sarah worked for the Youth and Education Law Project as a student attorney, interned in the Office of the General Counsel at Boston Children's Hospital, and served as an intern to Judge Allison D. Burroughs, U.S. District Court for the District of Massachusetts, prior to joining Ropes & Gray.

Experience

  • Counsels clients on complex regulatory issues, including those related to the Stark Law, Anti-Kickback Statute, False Claims Act, Civil Monetary Penalties Law, Medicare and Medicaid participation and reimbursement requirements, corporate practice of medicine, and HIPAA.
  • Defends health care companies subject to health care fraud investigations by federal and state enforcement agencies and to False Claims Act litigation.
  • Experience conducting internal investigations pursuant to both whistleblower and other compliance concerns. 
  • Advises clients on internal audits and, if necessary, preparation and negotiation of self-disclosures to federal and state agencies and of voluntary repayments to Medicare Administrative Contractors.
  • Advises clients on compliance risk assessments, programs, and policies.
  • Counsels covered entities, contract pharmacies, and manufacturers on compliance with the 340B Drug Discount Program.
  • Advises pharmaceutical companies regarding federal drug price reporting requirements under the Medicaid Drug Rebate Program, 340B Drug Pricing Program, and the Inflation Reduction Act. 
  • Counsels academic medical centers, higher education institutions, pharmaceutical companies, and biotechnology firms regarding allegations of research misconduct and other issues relating to the integrity or reliability of scientific data.
  • Advises academic medical centers, higher education institutions, pharmaceutical companies, and biotechnology firms on regulatory and compliance issues relating to clinical research.
  • Advises on regulatory considerations for transactions by health care entities and investors in the health care industry.

Areas of Practice